Albiges L et al. TiNivo: Safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2021;32(1):97-102. Abstract
Atkins MB et al. Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC. Gastrointestinal Cancers Symposium 2022;Abstract 362.
Choueiri TK et al. Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564. ASCO 2022;Abstract 4512.
Choueiri TK et al. Inhibition of hypoxia-inducible factor-2-alpha in renal cell carcinoma with belzutifan: A phase 1 trial and biomarker analysis. Nat Med 2021;27(5):802-5. Abstract
Choueiri TK et al. TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor. ASCO 2022;Abstract TPS4605.
Jonasch E et al. Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up. ASCO 2022;Abstract 4509.
McDermott D et al. Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2-alpha (HIF-2-alpha) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC). ESMO 2021;Abstract 656M0.
Motzer R et al. Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). ESMO 2021;Abstract 661P.
Motzer RJ et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(7):888-98. Abstract
Pal SK et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. Lancet 2021;397(10275):695-703. Abstract
Pal SK et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: Results from the COSMIC-021 Study. J Clin Oncol 2021;39(33):3725-36. Abstract
Pal SK et al. CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma. ASCO GU 2021;Abstract TPS370.
Rini BI et al. Maturation of overall survival (OS) in TIVO-3 with long-term follow-up. ASCO 2022;Abstract 4557.
Rini BI et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. ASCO 2021;Abstract 4500.